CytoSorbents Corporation is a development stage critical care focused immunotherapy company using blood purification to modulate inflammation to preventing or treating multiple organ failure in life-threatening illnesses. The technology is based upon biocompatible, highly porous polymer sorbent beads that are capable of extracting unwanted substances, such as drugs, dangerous chemicals, toxins, cytokines, free hemoglobin, and antibodies, from blood and other bodily fluids. In addition to CytoSorb, the Company is developing other products utilizing its adsorbent polymer technology that have not received regulatory approval including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
|Headquarters||7 Deerpark Dr Ste K|
MONMOUTH JUNCTION, NJ, United States 08852-1921
|Chairman of the Board||Al Kraus|
|President, Chief Executive Officer, Director||Phillip Chan|
|Chief Financial Officer||Kathleen Bloch|
|Chief Operating Officer||Vincent Capponi|
|Chief Medical Officer||Robert Bartlett|
|Shares Out.||24.5M||Book Value||$0.10|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||68.2|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-126.64%|
*GAAP = prior to non-GAAP analyst adjusted earnings.